Article

Apoptosis not only culprit in cell death

Apoptosis may be the best characterized form of programmed cell death-but it isn’t in isolation, said Joan W. Miller, MD.

New Orleans-Apoptosis may be the best characterized form of programmed cell death-but it isn’t in isolation, said Joan W. Miller, MD.

Alternative pathways are also at work, said Dr. Miller, chief and chairwoman, Department of Ophthalmology, Massachusetts Eye and Ear, Boston.   

Past research has focused on the mechanisms of cell death in the hopes of identifying therapeutic targets in degenerative retinal disease.

Previously, Dr. Miller said, apoptosis was thought to be the main mechanism of photoreceptor degeneration, but research shows it is not.

“Indeed, the caspase enzymes-which play a central role for inducing apoptosis-are activated in dying photoreceptor cells in experimental modes,” Dr. Miller said. “Paradoxically, inhibiting caspases doesn’t sufficiently protect against cell loss.”

Dr. Miller pointed out the involvement of other cell death mechanisms-specifically mentioning accumulating evidence demonstrating nonapoptotic forms of cell death, such as autophagy and necrosis, which are also regulated by specific molecular machinery, such as autophangy-related proteins and receptor-interacting protein RIP kinases, respectively.

“Certainly there are different pathogenesis,” she said. “There are different pathways, redundant and complimentary, for all these different diseases and some are overlapping.”

The key point, she said, is a research focus on combination therapy in order to achieve neuroprotection. By identifying alternative cell death pathways and understanding how to inhibit them, we can prevent vision loss in multiple eye disorders.

For more articles in this issue of Ophthalmology Times Conference Brief click here.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.